• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dabigatran Compared With Rivaroxaban vs Warfarin-Reply.

作者信息

Parks Anna L, Redberg Rita F

机构信息

University of California, San Francisco, San Francisco, California.

出版信息

JAMA Intern Med. 2017 May 1;177(5):744. doi: 10.1001/jamainternmed.2017.0571.

DOI:10.1001/jamainternmed.2017.0571
PMID:28460106
Abstract
摘要

相似文献

1
Dabigatran Compared With Rivaroxaban vs Warfarin-Reply.达比加群与利伐沙班对比华法林——回复
JAMA Intern Med. 2017 May 1;177(5):744. doi: 10.1001/jamainternmed.2017.0571.
2
Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study.达比加群、利伐沙班和华法林导致胃肠道出血的比较风险：基于人群的队列研究。
BMJ. 2015 Apr 24;350:h1857. doi: 10.1136/bmj.h1857.
3
Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation.口服抗凝剂在新诊断房颤老年患者中的性别特异性比较疗效
Circ Cardiovasc Qual Outcomes. 2017 Apr;10(4). doi: 10.1161/CIRCOUTCOMES.116.003418.
4
Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.阿哌沙班与其他口服抗凝剂治疗老年非瓣膜性心房颤动患者的有效性和安全性比较。
Curr Med Res Opin. 2017 Oct;33(10):1745-1754. doi: 10.1080/03007995.2017.1334638. Epub 2017 Aug 29.
5
Safety of novel oral anticoagulants compared with uninterrupted warfarin for catheter ablation of atrial fibrillation.新型口服抗凝剂与不间断使用华法林相比用于房颤导管消融术的安全性。
Ann Pharmacother. 2015 Mar;49(3):278-84. doi: 10.1177/1060028014563950. Epub 2014 Dec 16.
6
Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.达比加群、利伐沙班和阿哌沙班与华法林相比治疗非瓣膜性心房颤动的有效性和安全性。
J Am Heart Assoc. 2016 Jun 13;5(6):e003725. doi: 10.1161/JAHA.116.003725.
7
A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.一项全国性注册研究，旨在比较服用口服抗凝剂的心房颤动患者的出血率。
Eur Heart J Cardiovasc Pharmacother. 2017 Jan;3(1):28-36. doi: 10.1093/ehjcvp/pvw031. Epub 2016 Sep 27.
8
Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.低剂量非维生素K拮抗剂口服抗凝药与华法林在房颤患者中的有效性和安全性：倾向评分加权的全国队列研究
BMJ. 2017 Feb 10;356:j510. doi: 10.1136/bmj.j510.
9
Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation: Systematic Review and Meta-Analysis.利伐沙班与达比加群或华法林在心房颤动卒中预防真实世界研究中的比较：系统评价和荟萃分析
Stroke. 2017 Apr;48(4):970-976. doi: 10.1161/STROKEAHA.116.016275. Epub 2017 Feb 17.
10
Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care.利伐沙班与华法林及达比加群用于房颤治疗：丹麦常规医疗中的比较有效性与安全性
Pharmacoepidemiol Drug Saf. 2016 Nov;25(11):1236-1244. doi: 10.1002/pds.4034. Epub 2016 May 27.

引用本文的文献

1
Incidence and Risk Factors of Pulmonary Hypertension After Venous Thromboembolism: An Analysis of a Large Health Care Database.静脉血栓栓塞后肺动脉高压的发生率和危险因素：大型医疗保健数据库分析。
J Am Heart Assoc. 2022 Jul 19;11(14):e024358. doi: 10.1161/JAHA.121.024358. Epub 2022 Jul 15.
2
Risk of hospitalised bleeding in comparisons of oral anticoagulant options for the primary treatment of venous thromboembolism.口服抗凝药物治疗静脉血栓栓塞症的主要治疗方案比较的住院出血风险。
Br J Haematol. 2019 Jun;185(5):903-911. doi: 10.1111/bjh.15857. Epub 2019 Mar 28.
3
Oral anticoagulation therapy and subsequent risk of venous thromboembolism in atrial fibrillation patients.
口服抗凝治疗与心房颤动患者随后发生静脉血栓栓塞的风险。
Curr Med Res Opin. 2019 May;35(5):837-845. doi: 10.1080/03007995.2018.1541445. Epub 2018 Dec 3.
4
All-Cause Mortality Risk with Direct Oral Anticoagulants and Warfarin in the Primary Treatment of Venous Thromboembolism.直接口服抗凝剂与华法林在静脉血栓栓塞症初始治疗中的全因死亡率风险。
Thromb Haemost. 2018 Sep;118(9):1637-1645. doi: 10.1055/s-0038-1668521. Epub 2018 Aug 13.